Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.51 and traded as high as $0.73. Xtant Medical shares last traded at $0.69, with a volume of 126,832 shares trading hands.
Xtant Medical Stock Performance
The company has a market capitalization of $99.25 million, a price-to-earnings ratio of -5.49 and a beta of 0.35. The stock has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.51. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88.
Institutional Trading of Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC boosted its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the period. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Further Reading
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
